Lexicon Pharmaceuticals (LXRX) reported quarterly earnings results on Tuesday, May-3-2016. The company reported $-0.34 earnings per share for the quarter, missing the analyst consensus estimate by $-0.04. Analysts had a consensus of $-0.30. The company posted revenue of $12.50 million in the period, compared to analysts expectations of $11.11 million. The company’s revenue was up 594.4% compared to the same quarter last year. During the same quarter in the previous year, the company posted $-0.04 EPS.
Many Wall Street Analysts have commented on Lexicon Pharmaceuticals. Company shares were Reiterated by Wedbush on Mar 2, 2016 to “Outperform”, Firm has raised the Price Target to $ 28 from a previous price target of $26 .
Lexicon Pharmaceuticals opened for trading at $13.86 and hit $14.31 on the upside on Monday, eventually ending the session at $14.25, with a gain of 3.19% or 0.44 points. The heightened volatility saw the trading volume jump to 5,98,928 shares. Company has a market cap of $1,479 M.
Lexicon Pharmaceuticals Inc. (Lexicon) is a biopharmaceutical company. The Company is focused on the development of treatments for human disease. The Company is engaged in the development of two drug candidates: telotristat etiprate (LX1032) and sotagliflozin (LX4211). The Company’s telotristat etiprate is an orally delivered small molecule drug candidate as a treatment for carcinoid syndrome. It has completed two Phase II clinical trials and is conducting a single Phase III clinical trial of telotristat etiprate in carcinoid syndrome patients. The Company’s sotagliflozin is an orally delivered small molecule drug candidate as a treatment for type 1 and type 2 diabetes. The Company has completed two Phase II clinical trials of sotagliflozin in type 2 diabetes patients and an additional clinical trial of sotagliflozin in type 2 diabetes patients with renal impairment. It has also completed a Phase II clinical trial of sotagliflozin in type 1 diabetes patients.